Timing of Temporary Mechanical Circulatory Support in Cardiogenic Shock: Pathophysiological Rationale, ClinicalEvidence, and Future Directions

Background Cardiogenic shock (CS) remains a life-threatening condition associated with high mortality despite advances in revascularization, pharmacological therapy, intensive care, and temporary mechanical circulatory support (MCS). Increasing evidence suggests that the effectiveness of MCS may depend not only on device selection, but also on the timing of implantation and the stage of shock at which support is initiated. Methods This narrative review summarizes current evidence on the timing of temporary MCS initiation in cardiogenic shock. The review focuses on the pathophysiological rationale for early intervention, available MCS devices, definitions of early and late support, shock team protocols, observational studies, registries, and contemporary randomized trials evaluating MCS strategies in selected CS populations. Results The progression of cardiogenic shock involves a self-amplifying cascade of hemodynamic deterioration, systemic inflammation, metabolic derangement, and end-organ dysfunction. Early MCS may theoretically interrupt this cascade by restoring systemic perfusion and reducing ventricular workload before irreversible multiorgan injury develops. Observational studies and protocolized shock initiatives suggest that earlier MCS deployment within multidisciplinary systems of care may be associated with improved outcomes. Recent randomized evidence has strengthened the role of microaxial flow pump support in selected patients with infarct-related cardiogenic shock, while also demonstrating that routine early VA-ECMO should not be applied indiscriminately. Overall, current data support a phenotype-specific and risk-adapted approach rather than universal early MCS implantation. Conclusion The timing of temporary MCS initiation is an important but unresolved issue in contemporary cardiogenic shock management. Current evidence supports timely, individualized MCS use in carefully selected patients within structured multidisciplinary care pathways. Future studies should define standardized timing criteria, identify optimal therapeutic windows, and clarify which shock phenotypes benefit most from early mechanical support.